课题基金 / 基金详情

AMINOGLYCOSIDE TO CORRECT CELLULAR DEFECT IN CF AIRWAYS EPITHELIA MUTATIONS

AMINOGLYCOSIDE TO CORRECT CELLULAR DEFECT IN CF AIRWAYS EPITHELIA MUTATIONS
氨基糖苷可纠正 CF 气道上皮突变的细胞缺陷
批准号：
6115535
负责人：
JOSEPH Mark PILEWSKI
金额：
$2.06万
依托单位：
CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6115535
关键词：
child (0-11) chloride channels clinical research clinical trial phase I cystic fibrosis gentamicins human subject human therapy evaluation metabolism disorder chemotherapy respiratory epithelium

项目摘要

项目成果

JOSEPH Mark PILEWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of the study is to perform a double-blinded study to test the avility of aminoglycoside to induce read-through of stop mutations and restore functional CFTR protein in the nasal epithelium. Cystic fibrosis patients with the stop mutation G542X, R553X, W1282X or R1162X will be recruited. Gentamicin will be applied to the nasal epithelium of one nostril then the contralateral nostril will receive dilulent alone. One assay will be used to assess restoration of functional CFTR. This assay is nasal potential difference measurement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical/Biostatistics Core
Clinical/Biostatistics Core
Clinical/Biostatistics Core
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY OF AEROSOLIZED
海外基金